Elicio Therapeutics Accounts Payable

As of the most recent data (June 2026), ELTX shows a accounts payable of $840K. That compares with $3.9M in the prior-year period — down 78.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ELTX's accounts payable is now $840K (was $3.9M) — a 78.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Elicio Therapeutics is outperforming or lagging.

Tracking ELTX's accounts payable over time shows whether Elicio Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $840K That compares with $3.9M in the prior-year period — down 78.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Elicio Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $840K) with ownership activity and broader fundamentals.